Key result
Clopidogrel response variability affects ~30% of patients, potentially attenuating clinical benefit against arterial thrombotic events.
Why the study?
The clinical benefit of clopidogrel may be attenuated by variability of response in up to 30% of patients, and the best laboratory procedure to screen for this variability remains undetermined.
Design
Review
Authors
Loading...
May attenuate antiplatelet efficacy in substantial subsets; leaves open standardized testing and alternative regimens pending randomized trials.
Up to 30% of patients exhibit variability in response to clopidogrel due to multiple mechanisms, highlighting the need for optimal laboratory screening procedures.
Nguyen et al. (2006) conducted a review in Arterial thrombotic events. Clopidogrel was evaluated. Clopidogrel response variability affects up to 30% of patients, potentially attenuating its clinical benefit in reducing arterial thrombotic events due to dosing, interactions, and genetics.